Testing Sodium Bicarbonate and Exercise in Chronic Kidney Disease
Tests sodium bicarbonate and exercise in adults with chronic kidney disease.
Plain-language title generated from the registry record
Registry title: Neurovascular Regulation During Exercise in Humans With Chronic Kidney Disease: Sympatholysis in CKD
Key facts
- Where
- Atlanta and Decatur, United StatesSee the 2 sites
- Phase
- Phase 2
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 40 and 75 years old?
Source: NCT05928936, who can take part
Where in United States
- Emory ClinicAtlanta, United StatesTaking people
- Atlanta VA Medical CenterDecatur, United StatesTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Emory University
- Trial code
- NCT05928936
- Record updated
- 30 October 2026
- Original description
The goals of this project are to investigate the mechanisms and potential therapies related to exercise capacity in persons with chronic kidney disease (CKD).Read full original descriptionShow less
Neurovascular Regulation During Exercise in Humans With Chronic Kidney Disease: Sympatholysis in CKD
The goals of this project are to investigate the mechanisms and potential therapies related to exercise capacity in persons with chronic kidney disease (CKD).
Inclusion: patients with CKD (Stages III and IV), kidney transplant recipients with varying degrees of kidney function, or persons without kidney disease as matched study controls; sedentary and do not regularly exercise (defined as exercising < 20 minutes twice per week); CKD patients must have stable renal function (no greater than a decline of estimated glomerular filtration (eGFR) of 1 cc/min/1.73 m2 per month over the prior 6 months) and baseline serum bicarbonate 22-24 mmol/L; comorbid hypertension.
Exclusion: current treatment with bicarbonate; ongoing drug or alcohol abuse; treatment with central α-agonists (clonidine); surgery within the past 3 months; current use of immunosuppressive medications (including but not limited to steroids, cyclophosphamide, calcineurin inhibitors, mycophenolate, biologics, methotrexate, etc); any serious disease that might influence survival; clinical evidence of heart failure; symptomatic heart disease by EKG, stress test, and/or history; myocardial infarction or cerebrovascular accident within the past six months; uncontrolled hypertension (BP>170/100 mm Hg); peripheral arterial disease; arteriovenous (AV) fistula/graft; any contraindication to MR scanning including cardiac pacemaker, cochlear implants, neurostimulators, implanted devices with metal, any metal in the body that could pose a hazard during scanning, history of claustrophobia; severe CKD (eGFR<15 cc/min); anemia with hemoglobin <10 g/dL; volume overload or ejection fraction below 45%; metabolic alkalosis; diabetic neuropathy, autonomic dysfunction; low BP<100/50 mm Hg; pregnancy or plans to become pregnant; inability to exercise on a stationary bicycle; contraindication to temporary withdrawal of α- and β-blockers; class 3 obesity (BMI>40); hypo- or hyperkalemia (K<3.5meq/L, K>5.0 meq/L).